Poor medication adherence has long been the elephant in the counseling room. This common, age-old problem has the potential to paralyze clinical trials, but with no viable solution, sponsors and CROs are forced to ignore it.
But this is changing.
Incorporating advanced technologies, including smart packaging and powerful data analytics, is driving a revolution in compliance monitoring, accelerating drug development time, reducing clinical research costs and making trials safer for participants.
The story ends here
Poor adherence to investigational products during clinical trials is a costly problem.
Shocking statistic: Each participant in a phase III clinical trial is on average responsible for Cost of $42,000 However one third not attached to the 100th day. At all stages, 50% of patients Admit non-adherence to the dosing regimen.
This is an issue that negatively impacts patient outcomes, leads to underestimation of product efficacy and can threaten study success.
Research capacity is critical in clinical trial design. The higher the research power, the higher the probability of detecting the true effect of the drug. However, it reduced effect size and increased variability when subjects did not take their medication as directed.
As research planners know, if power is to be maintained, any decline in adherence must be dealt with through costly, labor-intensive ways of increasing the number of research participants. Therefore, non-adherence has a direct impact on the cost and duration of clinical trials.
However, traditional methods of monitoring adherence, such as pill counting, self-reporting, or biomarker measurements, are simply not sensitive enough to provide overall actionable information. They are open to bias, provide only snapshots of medication-taking behavior, and place additional burdens on both sites and patients.
None of this is new information — sponsors and CROs have faced the same problems for decades — but it has been swept away in the absence of a viable solution.
technological revolution
Digital compliance monitoring that combines connected packaging and powerful data analytics is changing the conversation.
Smart packaging, such as connected prefilled syringes, can collect basic information such as whether the injection was completed, time and date of administration, drug type, batch number, and expiration date.
This data is then streamed to a cloud-based platform for sophisticated analysis of medication-taking behavior. The visualizations it produces allow research teams to spot erratic dosing patterns, allow for risk stratification, and guide individualized interventions that take into account the complexities of poor medication adherence.
The approach can even be integrated into third-party apps, such as patient-facing apps designed to continually encourage compliance and engagement with the protocol.
Crucially, it provides a complete and accurate understanding Patient Adherence Behavior and Risk Indicators This is most important for learning success.
future trials
Clinical trials are undergoing two separate but interconnected revolutions—and digital adherence monitoring plays a central role in both.
In recent years, there has been an overall shift to patient-centred research in order to improve retention rates, at least in part.
For decades, sponsors and CROs have tried to make up for this shortfall by recruiting alternative participants. However, this strategy is prohibitively expensive, and the era of personalized medicine that limits the population of eligible patients is rapidly making it unviable.
Noncompliance can be an exit warning sign, providing clues about poor product efficacy, intolerable side effects, or problems with administration, all of which can lead to poor retention.
At the same time, we have also witnessed the digital transformation of the industry. In recent years, a variety of digital health services and applications have been designed to make the long and tortuous road to market entry shorter, faster and more efficient.
From electronic data acquisition to wearable sensors, each has the potential to simplify or optimize an element of clinical trials. But no factor affects the chances of a study’s success more than medication adherence.
The literature shows that the main source clinical trial failure Efficacy has not been proven for the past 30 years.
Security is another major reason for failure, but this result does not necessarily mean that the drug is unsafe.For example, incorrect dosing due to poor compliance may result in adverse event Can not accurately reflect the effect of the product.
Ultimately, the reasons why studies fail are as varied and complex as the trials themselves. However, there is one common denominator among the most common factors in efficacy, safety, and dose selection—that is, poor medication adherence.
turn the tide
Technological innovation is the key to disrupting the status quo, optimizing clinical trials, and ultimately addressing decades of poor adherence.
To embrace this potential, practice-changing, integrated tools such as the digital adherence monitoring ecosystem are rapidly being embedded into daily workflows and helping to reshape the landscape to ensure efficient, robust 21st century research.
Photo: Warchi, Getty Images
